{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:58:22Z","timestamp":1792486702953,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00198-023-06672-3","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T08:04:35Z","timestamp":1674115475000},"page":"671-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Management of bone loss due to endocrine therapy during cancer treatment"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-0201","authenticated-orcid":false,"given":"Maryam I.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"6672_CR1","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37:2916\u20132946","journal-title":"J Clin Oncol"},{"key":"6672_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00198-011-1724-9","volume":"23","author":"M Reuss-Borst","year":"2012","unstructured":"Reuss-Borst M, Hartmann U, Scheede C, Weiss J (2012) Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic. Osteoporos Int 23:1437\u20131444","journal-title":"Osteoporos Int"},{"key":"6672_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"6672_CR4","doi-asserted-by":"publisher","first-page":"713700","DOI":"10.3389\/fendo.2021.713700","volume":"12","author":"T Hyder","year":"2021","unstructured":"Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM (2021) Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne) 12:713700","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6672_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"TA Guise","year":"2006","unstructured":"Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11:1121\u20131131","journal-title":"Oncologist"},{"key":"6672_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209\u2013219","journal-title":"N Engl J Med"},{"key":"6672_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11914-019-00536-8","volume":"17","author":"S Ameb","year":"2019","unstructured":"Ameb S, Salawu A, Brown JE (2019) Bone health in men with prostate cancer: review article. Curr Osteoporos Rep 17:527\u2013537","journal-title":"Curr Osteoporos Rep"},{"key":"6672_CR8","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"6672_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL, Halabi S, Hars V et al (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683\u2013689","journal-title":"Eur J Cancer"},{"key":"6672_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jocd.2014.08.001","volume":"19","author":"J Lu","year":"2016","unstructured":"Lu J, Shin Y, Yen MS, Sun SS (2016) Peak bone mass and patterns of change in total bone mineral density and bone mineral contents from childhood into young adulthood. J Clin Densitom 19:180\u2013191","journal-title":"J Clin Densitom"},{"key":"6672_CR11","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-017-4189-7","volume":"28","author":"K Briot","year":"2017","unstructured":"Briot K, Geusens P, Em Bultink I, Lems WF, Roux C (2017) Inflammatory diseases and bone fragility. Osteoporos Int 28:3301\u20133314","journal-title":"Osteoporos Int"},{"key":"6672_CR12","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s12094-022-02872-1","volume":"24","author":"S Castaneda","year":"2022","unstructured":"Castaneda S, Casas A, Gonzalez-Del-Alba A, Martinez-Diaz-Guerra G, Nogues X, Ojeda Thies C, Torregrosa Suau O, Rodriguez-Lescure A (2022) Bone loss induced by cancer treatments in breast and prostate cancer patients. Clin Transl Oncol 24:2090\u20132106","journal-title":"Clin Transl Oncol"},{"key":"6672_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsbmb.2015.07.018","volume":"161","author":"HJ Chan","year":"2016","unstructured":"Chan HJ, Petrossian K, Chen S (2016) Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells. J Steroid Biochem Mol Biol 161:73\u201383","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6672_CR14","doi-asserted-by":"publisher","first-page":"111321","DOI":"10.1016\/j.mce.2021.111321","volume":"531","author":"D Molehin","year":"2021","unstructured":"Molehin D, Filleur S, Pruitt K (2021) Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. Mol Cell Endocrinol 531:111321","journal-title":"Mol Cell Endocrinol"},{"key":"6672_CR15","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1210\/jc.2001-011902","volume":"87","author":"S Issa","year":"2002","unstructured":"Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, Schweikert HU (2002) Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab 87:5401\u20135407","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR16","doi-asserted-by":"crossref","unstructured":"Chen JF, Lin PW, Tsai YR, Yang YC, Kang HY (2019) Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy. Cells 8(11):1318","DOI":"10.3390\/cells8111318"},{"key":"6672_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrendo.2013.179","volume":"9","author":"SC Manolagas","year":"2013","unstructured":"Manolagas SC, O\u2019Brien CA, Almeida M (2013) The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 9:699\u2013712","journal-title":"Nat Rev Endocrinol"},{"key":"6672_CR18","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1038\/onc.2017.94","volume":"36","author":"I Bado","year":"2017","unstructured":"Bado I, Gugala Z, Fuqua SAW, Zhang XH (2017) Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene 36:4527\u20134537","journal-title":"Oncogene"},{"key":"6672_CR19","doi-asserted-by":"crossref","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC (2018) Screening to prevent osteoporotic fractures: an evidence review for the US Preventive Services Task Force. Rockville (MD) Report No: 15-05226-EF-1","DOI":"10.1001\/jama.2018.6537"},{"key":"6672_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"key":"6672_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"6672_CR22","doi-asserted-by":"publisher","first-page":"101780","DOI":"10.1016\/j.berh.2022.101780","volume":"36","author":"HP Dimai","year":"2022","unstructured":"Dimai HP, Fahrleitner-Pammer A (2022) Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol 36:101780","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6672_CR23","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention T (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"6672_CR26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045","journal-title":"Mayo Clin Proc"},{"key":"6672_CR27","doi-asserted-by":"publisher","first-page":"e10549","DOI":"10.1002\/jbm4.10549","volume":"5","author":"HH Malluche","year":"2021","unstructured":"Malluche HH, Chen J, Lima F, Liu LJ, Monier-Faugere MC, Pienkowski D (2021) Bone quality and fractures in women with osteoporosis treated with bisphosphonates for 1 to 14 years. JBMR Plus 5:e10549","journal-title":"JBMR Plus"},{"key":"6672_CR28","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-021-01587-x","volume":"81","author":"LPB Elbers","year":"2021","unstructured":"Elbers LPB, Raterman HG, Lems WF (2021) Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81:1645\u20131655","journal-title":"Drugs"},{"key":"6672_CR29","doi-asserted-by":"publisher","first-page":"e10629","DOI":"10.1002\/jbm4.10629","volume":"6","author":"M Wang","year":"2022","unstructured":"Wang M, Wu YF, Girgis CM (2022) Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. JBMR Plus 6:e10629","journal-title":"JBMR Plus"},{"key":"6672_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM, Reginster JY, Al-Daghri N et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34:695\u2013714","journal-title":"Aging Clin Exp Res"},{"key":"6672_CR31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101105","volume":"15","author":"I Laura","year":"2021","unstructured":"Laura I, Felicia B, Alexia C, Aude M, Florence B, Murielle S, Rafik K, Jean-Jacques B, Pierre B (2021) Which treatment to prevent an imminent fracture? Bone Rep 15:101105","journal-title":"Bone Rep"},{"issue":"1","key":"6672_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256","journal-title":"Osteoporos Int"},{"key":"6672_CR35","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Oden A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757","journal-title":"Osteoporos Int"},{"key":"6672_CR36","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-021-06078-z","volume":"32","author":"FL Dos Santos","year":"2021","unstructured":"Dos Santos FL, Abreu LG, Calderipe CB, Martins MD, Schuch LF, Vasconcelos ACU (2021) Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int 32:2449\u20132459","journal-title":"Osteoporos Int"},{"key":"6672_CR37","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","volume":"105","author":"DM van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Guanabens N, Eastell R, Ralston SH, Zillikens MC (2020) Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab 105:1682\u20131699","journal-title":"J Clin Endocrinol Metab"},{"key":"6672_CR38","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP, Engelke K, Keaveny TM et al (2021) Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res 36:2139\u20132152","journal-title":"J Bone Miner Res"},{"key":"6672_CR39","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"6672_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226","journal-title":"J Bone Miner Res"},{"key":"6672_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"6672_CR42","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","volume":"31","author":"MR McClung","year":"2020","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31:2231\u20132241","journal-title":"Osteoporos Int"},{"key":"6672_CR43","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"6672_CR44","doi-asserted-by":"publisher","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone 162:116480","journal-title":"Bone"},{"key":"6672_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, Carlino F, Giunta EF, Franzese E, Guerrera LP, Di Lauro V, Ciardiello F, Daniele B, Orditura M (2021) Cancer treatment-induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy. Curr Treat Options Oncol 22:45","journal-title":"Curr Treat Options Oncol"},{"key":"6672_CR46","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663","journal-title":"Ann Oncol"},{"key":"6672_CR47","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org EGCEa (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 30:1194\u20131220","journal-title":"Ann Oncol"},{"key":"6672_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jbo.2013.08.001","volume":"2","author":"AJ Lomax","year":"2013","unstructured":"Lomax AJ, Yee Yap S, White K et al (2013) Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN Trial. J Bone Oncol 2:145\u2013153","journal-title":"J Bone Oncol"},{"key":"6672_CR49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398\u2013405","journal-title":"Ann Oncol"},{"key":"6672_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"6672_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bju.14015","volume":"121","author":"Y Poon","year":"2018","unstructured":"Poon Y, Pechlivanoglou P, Alibhai SMH, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 121:17\u201328","journal-title":"BJU Int"},{"key":"6672_CR52","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00520-021-06490-5","volume":"30","author":"H Miyashita","year":"2022","unstructured":"Miyashita H, Satoi S, Cruz C, Kim SM, Patel VG (2022) Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Support Care Cancer 30:855\u2013863","journal-title":"Support Care Cancer"},{"key":"6672_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346","journal-title":"Lancet"},{"key":"6672_CR54","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"6672_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo TR, Chen CH (2017) Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res 5:18","journal-title":"Biomark Res"},{"key":"6672_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391\u2013420","journal-title":"Osteoporos Int"},{"key":"6672_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","volume":"28","author":"A Diez-Perez","year":"2017","unstructured":"Diez-Perez A, Naylor KE, Abrahamsen B et al (2017) International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 28:767\u2013774","journal-title":"Osteoporos Int"},{"key":"6672_CR58","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jbmr.4178","volume":"36","author":"R Eastell","year":"2021","unstructured":"Eastell R, Black DM, Lui LY et al (2021) Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. J Bone Miner Res 36:236\u2013243","journal-title":"J Bone Miner Res"},{"key":"6672_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151","journal-title":"J Bone Miner Res"},{"key":"6672_CR60","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537","journal-title":"J Bone Miner Res"},{"key":"6672_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/bonekey.2013.138","volume":"2","author":"JH Krege","year":"2013","unstructured":"Krege JH, Wan X, Lentle BC et al (2013) Fracture risk prediction: importance of age, BMD and spine fracture status. Bonekey Rep 2:404","journal-title":"Bonekey Rep"},{"key":"6672_CR62","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00198-020-05294-3","volume":"31","author":"RL Barron","year":"2020","unstructured":"Barron RL, Oster G, Grauer A, Crittenden DB, Weycker D (2020) Determinants of imminent fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 31:2103\u20132111","journal-title":"Osteoporos Int"},{"key":"6672_CR63","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbmr.3722","volume":"34","author":"S Ferrari","year":"2019","unstructured":"Ferrari S, Libanati C, Lin CJF et al (2019) Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res 34:1033\u20131040","journal-title":"J Bone Miner Res"},{"key":"6672_CR64","doi-asserted-by":"crossref","unstructured":"Coleman R (2022) Bone-targeted agents and metastasis prevention. Cancers (Basel) 14(15):3640","DOI":"10.3390\/cancers14153640"},{"issue":"11","key":"6672_CR65","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cells10112944","volume":"10","author":"J Ban","year":"2021","unstructured":"Ban J, Fock V, Aryee DNT, Kovar H (2021) Mechanisms, diagnosis and treatment of bone metastases. Cells 10(11):2944","journal-title":"Cells"},{"key":"6672_CR66","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, Lesko LJ, Gong Y (2016) Osteonecrosis of the Jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). J Bone Miner Res 31:336\u2013340","journal-title":"J Bone Miner Res"},{"key":"6672_CR67","unstructured":"Crandall CJ, Newberry SJ, Diamant A, et al. (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 Report. Rockville (MD). Report No.: 12EHCO23-EF"},{"key":"6672_CR68","first-page":"S1","volume":"18","author":"S Levis","year":"2012","unstructured":"Levis S, Theodore G (2012) Summary of AHRQ\u2019s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm 18:S1-15 (discussion S13)","journal-title":"J Manag Care Pharm"},{"key":"6672_CR69","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE et al (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"6672_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12603-015-0652-3","volume":"21","author":"KS Khow","year":"2017","unstructured":"Khow KS, Shibu P, Yu SC, Chehade MJ, Visvanathan R (2017) Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: a systematic review. J Nutr Health Aging 21:83\u201391","journal-title":"J Nutr Health Aging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06672-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T09:08:37Z","timestamp":1679994517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06672-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6672"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06672-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}